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Printed in Belgium.The spread of HIV/AIDS, malaria and tuberculosis (TB) continues. These three diseases pose a threat to
societies around the globe, especially in the developing world. While they also affect the wider global
community, it is the poorest people in the world who are worst hit. The link between these diseases and
poverty is well established. There is no space for under-estimating the challenge that faces us all. 
The health crisisbesetting the developing world is not just a social and personal tragedy for the men, women
and children suffering from these diseases. It is also an economic and developmental catastrophe because
it attacks children and the active members of the population: young working adults, those who run
businesses, have children and raise them. The situation is particularly devastating in Africa. For these reasons,
HIV/AIDS, malaria and tuberculosis pose the gravest threat to Africa's survival and as a result, a challenge
to all mankind.
Equal opportunity for a healthy life is a cornerstone of all human societies. It is a test of our will to build
a world that is more in harmony with our fundamental values.
In order to confront these three major communicable diseases, action needs to be carried out on many
fronts at the same time. This approach is outlined in the aims of the European Union’s Action Programme
launched in February 2001. We must work towards economic and social development and continue the
struggle against poverty. We must make pharmaceuticals affordable, and develop effective new vaccines.
We also need to create peace and security, for without them nothing is possible.
We are ready to do more and to act quickly to contribute to the global efforts to control these diseases.
As the world’s largest donor of development aid, the European Commission and the European Union are
fully aware of this responsibility.
We have tripled our support to confront the three diseases in our regular assistance programmes for
developing countries. With the full support of the Member States and the European Parliament, the European
Commission has allocated in total more than an additional ¤1 billion to the Action Programme to date and
this is in addition to what we do through our regular channels already. More than ￿450 million will be
allocated over the next four years to research and development covering new pharmaceuticals and vaccines
for poverty-related diseases. 
The European Commission has strongly advocated ‘tiered pricing’of medicines since September 2000 and
this has just received a boost through the adoption of unprecedented legislation in the European Union:
this legislation seeks to prevent the re-importing of reduced-price medicines into Europe and therefore
encourages the pharmaceutical industry to make products available at near to cost of production price.
Some laboratories have already done so. I call on others to show the same willingness to make more progress
on this critical issue.
And access to affordable treatments has to go hand in hand with prevention as the core element to control
these diseases: information, education, communication and access to bed nets and condoms is often a
matter of life or death. We cannot afford any complacency until those vulnerable; particularly women and
children looked after by them, and have access to an informed choice of tools to protect themselves and
their families from these diseases.
This brochure explains our strategy  and gives an overview of our actions so far. We must continue to rally
everyone – researchers, the medical profession, industry, associations, civil society and politicians. History
will judge us harshly if we do not use our power to control HIV/AIDS, malaria and tuberculosis. We have
the knowledge, the technology, and the resources to address the enormous challenges posed by these
diseases. 
Commissioner Poul Nielson 
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30Summary and key messages
1. HIV/AIDS, malaria and tuberculosis (TB) are
major global health problems. On the one hand they
predominantly affect poor people in developing
countries, and on the other their occurrence
increases poverty. The three diseases pose a major
threat to development and to the global community.
2. The response to date has been characterised by
inadequate efforts which have prevented scaling up
of successful interventions, by collapsing health and
education systems, and by failure to develop new but
affordable products for treatment and care.
3. The international community has now made a
fresh commitment to tackle these three diseases
within the framework of the Millennium Declaration,
agreeing to reverse the spread of HIV and the
incidence of malaria by 2015. To achieve this target
donor countries have pledged to massively increase
overseas development assistance over the next few
years. 
4. In the context of this renewed international
commitment, the European Community has adopted
a comprehensive strategy for confronting the three
diseases. Building on the European Commission’s
areas of comparative advantage, the strategy entails
a series of actions to: (a) increase the impact of
existing interventions, (b) increase the affordability
of key pharmaceuticals, (c) encourage research in
and development of specific global public goods
targeting HIV/AIDS, malaria and tuberculosis and (d)
improve the effectiveness of global partnerships and
regional co-operation.
5. The EU is playing a key role in the international
response by developing and strengthening
partnerships with key stakeholders at global level,
working for increased harmonisation of donor
support, and by providing substantial support to the
Global Fund to Fight AIDS, Tuberculosis and Malaria.
6. At country level, the European Commission’s
strategy is aimed at creating a favourable
environment for an effective national response to the
three diseases through such measures as providing
support to social institutions and services, by
increased funding and lowering the prices of
pharmaceuticals and other essential commodities.
3HIV/AIDS, malaria and tuberculosis are commu-
nicable diseases that affect the poorest countries
disproportionately and cause enormous suffering
among households and communities. They feed
into the cycle of poverty and insecurity, creating an
obstacle to development. These diseases cross
borders and also affect the global community.
Progress has been made in the control of many of
the other communicable diseases over the last
few decades, however, HIV/AIDS, malaria and
tuberculosis are still far from showing signs of
regressing in most of the regions of the world. There
are only a few exceptions where recent successes
provides hope and direction.
Knowledge and tools to confront these diseases
exist and could significantly ease the burden and
decrease the spread of HIV/AIDS, malaria and
tuberculosis: education and health services for
those in greatest need, condoms, bed nets and
adequate care and treatment could prevent millions
of needless premature deaths.
HIV/AIDS
Today approximately 40 million people are infected
with HIV. More than 24 million people – including
almost five million children – have already died since
the beginning of the epidemic; 90% are from
developing countries, leaving behind a legacy of
more than 15 million orphans. More than three
million people died and another five million were
newly infected during 2002(
1). 
Africa, especially sub-Saharan Africa, is the region
most affected. HIV/AIDS, is responsible for 30% of
ill health and almost 40% of all deaths on the
continent. Sixty million Africans are either living with
HIV, have died of HIV/AIDS or they have lost their
parents to the disease. Inequality, poverty, limited
education and knowledge and lack of access to
prevention care and treatment fuel transmission. The
projected toll is likely to reach 55 million additional
deaths by 2020 in sub-Saharan Africa alone. 
Sixty per cent of adults infected in Africa are women
and they are often infected at a much younger age.
The spread of HIV/AIDS is rapidly increasing among
young girls and women. In addition to biological
reasons, this is caused by inequalities in information,
education, and empowerment. Economically, many
women are dependent on men, and often they
cannot control when and with whom and in what
circumstances they have sex. Response must be
gender sensitive. Specific strategies and
interventions must address women's and girls'
vulnerability and also mitigate the socio-economic
(1)
UNAIDS Epidemic update
2002.
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The State of the epidemics 
North America
980 000
5 Adults and children estimated to be living 
with HIV/AIDS, end 2002
Total: 42 million
Western Europe
570 000
North Africa &
Middle East
550 000
Sub-Saharan
Africa
29 400 000
Latin America
1 500 000
Caribbean
440 000
Eastern Europe 
& Central Asia
1 200 000
East Asia & Pacific
1 200 000
South & South-East Asia
6 000 000
Australia 
& New Zealand
15 000
Source:
UNAIDS, 2002impact on women. A recent study by the World
Bank(
2) has found that the long-term effects of
HIV/AIDS could result in economic collapse of the
worst affected countries. The study estimates that
in South Africa by 2050 the per capita income per
family will be half the amount it was in 1990.
Malaria
Malaria causes at least 3,000 deaths a day, more
than 90% of which are in Africa south of the Sahara.
Most of the victims are young children(
3). It is a
contributing factor to low birth weight, chronic
anaemia and weakened immunity for another some
two million premature deaths among the most
vulnerable. 
Besides premature deaths, malaria causes 500
million cases of acute illness and is one of the leading
causes of school and work absences, undermining
education and economic development. The disease
has hindered economic growth in Africa by as much
as 1.3% of the Gross Domestic Product (GDP) each
year. This means the GDP of African countries is
currently 32% lower than it might have been had
malaria been controlled two decades ago(
4).
Overall, the burden of malaria is increasing, mainly
in sub-Saharan Africa. Rural communities, especially
children under five years old and pregnant women,
are worst affected because they have less access to
effective treatment and prevention services and
commodities. The poorest in society are more
exposed to transmission due to poor sanitation,
nutrition and lack of access to prevention means
such as Insecticide Treated Nets (ITNs). 
Lack of education and knowledge about the disease
and limited access to effective prevention and
treatments leads to recurrent disease and premature
deaths, mainly in children and often taking place at
home, untreated, and often unrecorded. Global
climate changes, the discontinuation of many vector
control programmes, deforestation and the increase
of displaced persons have led to increased
morbidity. Morbidity translates into premature
deaths due to poor access to effective health
services and effective pharmaceuticals for
prevention and treatment, which are a cause and
consequence of the spread of resistant strains. 
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(2)
‘The Long Run Economic
Costs of AIDS: Theory and
an Application to South
Africa’, World Bank 2003.
(3)
Roll Back Malaria 
update March 2003.
(4)
Macroeconomics 
and Health: 
Investing in Health for
Economic Development.
Report of the Commission
on Macroeconomics and
Health, WHO, 
20 December 2001.
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5 Distribution of Endemic MalariaTuberculosis
One-third of the world’s population is infected with
tuberculosis. Eight million people develop the
disease and two million die every year. The global
incidence rate is growing at approximately 0.4% per
year, but much faster in sub-Saharan Africa and in
countries of the former Soviet Union(
5). Between
2000 and 2020, nearly one billion people will be
newly infected with tuberculosis, 200 million people
will become sick, and 35 million will die unless
current efforts to control the disease are greatly
strengthened and expanded.
Ninety-nine per cent of all tuberculosis sufferers live
in developing countries, where the largest majority
is poor people aged 15 to 54. Some 80% of all
tuberculosis cases are found in 22 ‘high burden’
countries concentrated in Africa and Southeast Asia.
Tuberculosis primarily affects the poorest in society.
Crowding, poor hygiene and malnutrition are
important risk factors, closely linked to poverty.
Access to prompt case detection, diagnostics and
treatment is the main tool for controlling trans-
mission and reducing the spread of the disease.
Those most vulnerable have less access to health
services and effective diagnosis and treatment.
HIV and tuberculosis speed up each other’s
progress. Tuberculosis accounts for about 15% of all
HIV/AIDS-related deaths worldwide, twice as many
in sub-Saharan Africa. The number of people
infected with both tuberculosis and HIV has already
soared to more than 10 million. These cases are more
difficult to diagnose and treat, contributing to the
expansion of tuberculosis multi-drug resistant (MDR)
strains. 
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Global TUBERCULOSIS
Control Report 2002.
5 Estimated TB incidence rates, 2001
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Source:
WHO, Report 2003The European Commission's early
response starts in 1987
Since 1987, the European Commission has deve-
loped an innovative strategy to confront HIV/AIDS,
tackled as a developmental problem in need of a
multisectoral approach aiming to reduce the spread
of HIV/AIDS in the developing world. It has since co-
operated with governments, NGOs, international
agencies, the United Nations, the private sector and
people living with HIV/AIDS. 
The European Commission HIV/AIDS Programme has
implemented interventions at national, regional
and international level in at least 90 developing
countries. These include preventive and care
measures, multisectoral support, research studies
and communication initiatives. In 1993, health
sector support became increasingly important for
the European Commission and the fight against
HIV/AIDS and other communicable diseases was
dealt with through support to that sector. 
The European Commission’s total support to health
in more than 100 developing countries from 1994 to
2001 amounts to some ￿5 billion, through a variety
of complementary financing mechanisms. This makes
an average annual expenditure of ￿625 million(
6).
The breakdown of financial instruments channelling
health aid during this time period was: 60% from
country and regional programmes, 25% from
humanitarian aid, 9% from research, 3% from
special budget lines, and 3% from NGO co-financing.
The breakdown by regions was: 59% for African,
Caribbean and Pacific (ACP) countries (which
includes most of the least developed countries), 17
for MEDA (Community assistance programme to the
countries of the Mediterranean basin), 11% for Asia,
9% for Latin America, 2% for CARDS (Community
assistance programme to the countries around the
western Balkans) and 1% for TACIS countries
(Community Assistance Programme to the Common-
wealth of Independent States).
European Commission support in the areas of health,
HIV/AIDS, and population (HAP) has strengthened
systems and provided for health services. It has also
involved extensive support granted to improving
capacity for procurement and distribution as part of
wider efforts to reform health systems.
There are many challenges that need to be overcome
if developing and developed countries are to make
substantial progress in confronting HIV/AIDS,
malaria and tuberculosis, which continue to pose
threats to global security, prosperity and deve-
lopment, as well as to the lives of millions of people.
(6)
Data from the ongoing
population and 
development evaluation,
and several services 
in EuropeAid, ECHO 
and DG RTD.
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Response has been inadequate 
in scale and scope The three epidemics remain 
out of control
The three epidemics are out of control, despite the
global efforts over past decades.
Some success stories are overshadowed by the
expanding epidemics.
In HIV/AIDS there are some success stories that may
lead the way: Thailand directed early preventive
efforts at injection drug users and commercial sex
establishments and decreased annual infection
rates (cohorts from military recruits) by a factor of
five during this last decade. 
Uganda developed preventive education campaigns
that mobilised leaders at all levels and in all sectors
and reduced HIV prevalence among pregnant women
in urban areas from a high of 29% in 1992 to 11% in
2000. 
Globally, HIV/AIDS is still expanding and access to
essential and affordable interventions is ina-
dequate: the use of condoms with non-regular
partners remains very low, only 12% of the
population has access to Voluntary Counselling and
Testing services (6% in Africa) and just 5% of
pregnant women have access to prevention of
mother-to-child-transmission (only 1% of the 27
million annual births in Africa)(
7).
Malaria prevention and effective treatment is still
very weak. The proportion of children under five
sleeping under insecticide-treated nets is on
average below 10%. Adequate preventive treatment
for pregnant women is high in countries such as
Malawi and Kenya (up to 68% of pregnant women).
However, in the rest of the malaria endemic coun-
tries in Africa, fewer than 5% of pregnant women
have access to prevention. 
With respect to malaria treatment, several studies
reveal that nearly 90% of all malaria treatment takes
place at home and in the majority of cases the anti-
malarial treatments were not appropriate. The
present extent and trend towards resistance to the
main pharmaceuticals used in Africa for malaria
treatment is further increasing.
More than half (55%) the world’s population lives
today in parts of countries providing supervised
treatment for tuberculosis (DOTS). However, these
cases detected and treated through DOTS represent
only one quarter of the estimated total. In fact,
Vietnam was the only high-burden country to have
reached targets for case detection and cure by the
end of year 2000. 
The high association with HIV/AIDS, low detection
rates and low compliance rates in some regions,
threatens to expand multi-drug resistant (MDR)
tuberculosis, an almost incurable disease for most
people in developing countries(
8).
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(7)
Coverage of selected
health services for HIV/AIDS
prevention and care 
in less developed 
countries in 2001, 
WHO, November 2002.
(8)
WHO Report 2002 
Global Tuberculosis Control,
Surveillance, Planning,
Financing WHO/CDS/
TUBERCULOSIS/
2002.295
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Source: WHO Report, 2003Scale of intervention must be increased
African countries have agreed to allocate 15% of their
national budgets to health (Abuja, April 2000), but
reality is still a long way from that target.
In the recent decade, Official Development Assistance
(ODA) has been decreasing. Overall, ODA to social
development and especially health and education has
often been characterised by piece-meal approaches,
lack of scale and slow administrative procedures.
The WHO-led Commission on Macroeconomics and
Health calculated that current actual spending on
health in the least developed countries(
9) (approxi-
mately  ￿13 per person per annum) needs to be
increased to at least ￿30 to ￿40 per person per
annum. This will require approximately ￿27 billion
per annum in donor grants by 2007, compared with
the ￿6 billion per annum currently available, and an
additional budgetary outlay from developing
countries of ￿23 billion by 2007. 
The same Commission also provided a detailed est-
imate of annual financial needs to cover HIV/AIDS,
malaria and tuberculosis, totalling ￿9.2 billion. This
is a minimum estimate for investments with imme-
diatepossible levels of delivery with an emphasis on
expanding the lower levels of district health systems,
such as health posts and outreach services. 
Subsequent studies have estimated rising global
resources needed for the three diseases. For
HIV/AIDS alone, the global resources needed for
prevention, care and orphan activities would be
above￿11.74 billion annually by 2007. Despite many
international agreements and commitments, at
present only a quarter of the funds needed to fight
HIV/AIDS, malaria and tuberculosis are available
annually, some ￿2.68 billion:  ￿1.51 for HIV/AIDS,
￿0.67 for tuberculosis, and ￿0.5 for malaria.
The research paradigm
The paradigm of just 10% of the world’s investments
on health research allocated to health problems
causing 90% of the world’s burden of disease
applies to HIV/AIDS, malaria and tuberculosis needs
in developing countries. One clear example is the
HIV/AIDS vaccine. 
Just  ￿430-470 million is invested worldwide in
HIV/AIDS vaccine research and development. This
means only about 2% of what the world spends
annually on HIV/AIDS prevention, research, and
treatment (￿16.77 billion) and less than 1% of
spending on all health and pharmaceutical-related
research and development (over ￿58.68 billion). 
Increasing current financing by at least ￿1.1 billion
would pay for developing 25 novel HIV/AIDS vaccine
candidates and testing the relevant candidates in
large-scale efficacy studies and establishing infra-
structure for trials in a diversity of regions. This
would set the conditions to aim at developing the
effective HIV/AIDS vaccine the world needs today
(possibly the most valuable global public good)
within this decade.
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(9)
The Least Developed 
Countries are presently 49:
Afghanistan, Angola,
Bangladesh, Benin, Bhutan,
Burkina Faso, Burundi,
Cambodia, Cape Verde,
Central African republic,
Chad, Comoros, Democratic
Republic of Congo, Djibouti,
Equatorial Guinea, Eritrea,
Ethiopia, Gambia, Guinea,
Guinea Bissau, Haiti, 
Kiribati, Lao People’s
Democratic Republic,
Lesotho, Liberia, 
Madagascar, Malawi,
Maldives, Mali, Mauritania,
Mozambique, Myanmar,
Nepal, Niger, Rwanda,
Samoa, Sao Tome and 
Principe, Senegal, Sierra
Leone, Solomon Islands,
Somalia, Sudan, Togo,
Tuvalu, Uganda, United
Republic of Tanzania,
Vanuatu, Yemen 
and Zambia 
(UNCTAD 2001  
http://www.unctad.org/
en/pub/ldcprofiles2001.
en.htm).Listening to the voices of civil society
and the importance of private sector
engagement
The determination of NGOs and civil society has been
very valuable in raising awareness, triggering
political commitments and countering the short-
comings of institutions and governments. Their
voices are crucial in keeping up the commitments
and directing resources in the most efficient and
equitable way. The involvement of People Living with
HIV/AIDS has also been groundbreaking(
10).
Amongst those affected, children bear the main
burden of malaria and when HIV/AIDS and tuber-
culosis affect their parents, their fragile livelihoods
are threatened, especially when they become
orphans(
11). The voices of children should also be
heard loud and clear in their call for a global
commitment to confront these epidemics.
Because often they affect employees and their
families during their most productive years, these
diseases add to labour costs and slow down growth
rates in many developing countries. As a result,
corporations have begun to understand the impor-
tance of providing health prevention and care schemes
for their employees.
Strategies on how to promote access to prevention,
treatment and care as well as on codes of conduct
by corporations operating in developing countries
are ongoing through the European Commission’s
Corporate Social Responsibility (CSR) initiatives. 
(10)
Declaration of Commitment
on HIV/AIDS. United
Nations General Assembly.
Special Session on
HIV/AIDS, June 2001.
(11)
A world fit for children.
United Nations Special
Session on Children, 
May 2002.
12The international community has reached consensus
around key goals for the new millennium. Three out
of the seven Millennium Development Goals (MDGs)
are related to health:
•  ‘Reduce child mortality’: reduce the proportion
of children who die before the age of five, by two
thirds between 1990 and 2015. 
•  ‘Improve maternal health’: reduce by three
quarters, between 1990 and 2015, the maternal
mortality ratio. 
•  ‘Combat HIV/AIDS, malaria and other diseases’:
have halted by 2015, and begun to reverse, the
spread of HIV/AIDS, and the incidence of malaria
and other major diseases.
Further targets more specific to each of the major
poverty-related diseases have been agreed to by the
international community:
1. The UN General Assembly Special Session on
HIV/AIDS set additional specific targets. It focused
on national strategies for HIV/AIDS-related issues
(prevention, treatment, care and multi-sectoral
strategies) by 2003, and on reducing HIV infection
among 15 to 24-year-olds by 25% in the worst
affected countries and globally by 2010. In addition,
the proportion of infants infected with HIV should be
reduced by 20% by 2005 and by 50% by 2010.
2. Because 90% of the world’s malaria burden is in
Africa, additional targets for the continent were
defined on 25 April 2000 at the African Roll Back
Malaria Summit in Abuja, Nigeria. The targets set
include ensuring access for at least 60% of those
suffering from malaria to affordable and appropriate
treatment within 24 hours of the onset of symptoms
and access for at least 60% of those at risk for
malaria to protective measures (such as insecticide-
treated nets for under-fives or chemo-prophylaxis for
pregnant women) by 2005. These targets would lead
to halving 1998 malaria mortality levels by the year
2010.
3. Tuberculosis targets for 2005 were endorsed at
the World Health Assembly on 5 May 2000. They aim
at detection of 70% of all cases and successful
treatment of 85% using the DOTS strategy by 2005,
and a reduction in prevalence and mortality rates to
half of the year 2000 estimate, by 2010.
The Millennium Development Goals
13Despite earlier efforts, it became clear that the poli-
cies, strategies and methods had to be reformulated
and refocused. Poor health and communicable
diseases received increasingly recognition as
serious impediments to development and a cause,
not only a consequence, of poverty. 
In 2000, the European Commission developed a
comprehensive, more strategic approach towards
confronting HIV/AIDS, malaria and tuberculosis. The
High Level Round Table held in September 2000 had
the dual purpose of initiating a broad-based
consultation on a new policy framework on commu-
nicable diseases and exploring more precisely how
the European Commission could use its comparative
advantage to complement existing global and
national initiatives on all levels. 
The Round Table was remarkable because of the
co-operation it fostered amongst six different
Directorates General of the Commission in charge of
different policy areas in producing the European
Commission's new comprehensive, coherent and
synergistic policy framework. The consultations led
to the European Commission’s programme for
action(
12) in February 2001. This new Programme for
Action: Accelerated action on HIV/AIDS, malaria and
tuberculosis in the context of poverty reduction,
established a broad and coherent Community
response for 2001-2006. It also marked a new era in
the Commission’s approach to tackling the three
major poverty-related diseases. 
The strategy builds on the experience of a coherent
comprehensive approach, the principle of country-led
development process, ownership, the interrelationship
of health and poverty and the importance of regional
and global action in support of countries efforts. It
is based on a multi-pronged strategy. 
1. Obtaining maximum impact of existing
interventions, services, and access to
commodities targeted at the major communicable
diseases affecting the poorest populations 
In principle, the major communicable diseases are
largely preventable/and or readily treatable using
existing low cost, effective multisectoral inter-
ventions. However, these do often not reach the most
vulnerable people in some developing countries
struggling to deliver essential healthcare with less
than ￿4.19 per capita per year. 
Optimising the impact of existing interventions,
services and commodities requires increased
support to strengthen health systems and a
continuum of prevention, care and treatment efforts.
It also requires scaled-up, multisectoral, targeted
support through innovative partnerships that reach
beyond the traditional health sector and services.
(12)
COM(2000) 585.
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Strategy for communicable diseases 
revisited in 2000 2.  Increasing affordability of key pharmaceuticals
through a comprehensive and synergistic global
approach
Increasing affordability of key pharmaceuticals can
only be achieved through a comprehensive global
approach that addresses the current global emer-
gency. Developing countries, in particular poor
populations, have inadequate access to affordable
services and key pharmaceuticals for several
reasons, including the effects of international and
national pricing policies, tariffs, taxation, and
implementation of intellectual property rights
agreements.
Options for further improving access and afford-
ability include: strengthening pharmaceutical
policies, developing local manufacturing capacities,
tiered pricing, voluntary licensing agreements,
parallel trading, technology transfer and increase in
the local capacity for production, use of both
generic and patented products, and review of tariff
and taxation options at country level.
3.  Increasing investment in research and
development of global goods targeting the three
major communicable diseases 
Research and development in the pharmaceutical
industry is generally driven by the demands of the
industrialised countries’ markets. Those diseases
prevalent in developing countries, where markets are
perceived to be small, are neglected. Just 10% of
global health research efforts target the diseases
that account for 90% of the global disease burden.
Research for tuberculosis and malaria reflect this
imbalance: while they account for 5.4% of the global
burden of disease, they only benefit from 0.41% of
global health research.
4. Increasing regional co-operation and global
partnerships
Efforts to confront the three diseases at country level
have to be strengthened and supported through
more regional co-operation if to be successful. Global
multilateral action and partnerships are needed for
developing countries: consensus to be taken into
account in global governance and rules for instance
as related to prices of products, priorities for
research and development co-operation.
There has been considerable progress made to
date in the areas defined under the Commission’s
strategy. Following is a brief summary of some key
elements.
15European Commission Support 
for Health, AIDS and Population 
in Country and Regional Programmes
The bulk of the European Commission’s deve-
lopment assistance for health and communicable
diseases is committed within regional and country
indicative programmes covering periods of four or
five years. These are developed as part of the
European Commission’s regional and country
strategy papers (CSPs) – instruments for guiding
Community assistance which are developed by the
Commission and the authorities of the recipient
country or region, in consultation with the Member
States and other development partners. CSPs may
be accessed on the Commission’s website at:
http://europa.eu.int/comm/development/body/
csp_rsp/csp_en.cfm.
The European Commission still provides support for
health, communicable diseases and population in
some countries through traditional project-type
assistance, however, the European Commission’s
current policy stresses investment in sector
programmes or general budget support. Unlike
traditional project-type aid, budget support provides
additional funding for recurrent expenditure, which
makes up the major part of the health budget.
The European Commission supports the deve-
lopment of a sector-wide approach (SWAP) in health
wherever feasible, combined with investment in
sector or sub-sector pooled (or ‘basket’) funds. This
approach has several advantages, including:
• Nationally owned and led.
• Potential for donors to invest in one single,
prioritised national health plan.
• Based on dialogue involving all key
stakeholders.
The European Commission regards HIV/AIDS as a
specific and pernicious threat to development in
many developing countries and is increasingly
highlighting HIV/AIDS in its dialogue with national
authorities. The European Commission recognises
that AIDS is not simply a health issue and that an
effective response requires actions in all sectors. This
is borne out in the CSPs of several of the worst
affected countries in Africa, which reinforces the case
for multisectoral actions to confront the HIV/AIDS
epidemic. They include HIV/AIDS prevention and
care activities in the strategies for the focal sectors
for European Commission co-operation 
16ACP countries have an additional allocation of
funds for all countries together (intra-ACPfunds) that
are available to support programmes aimed at
tackling problems and issues facing all of them.
European and international consensus
In addition to country and regional actions, the
European Commission has been proactive with
respect to its mandate for more coherent and co-
ordinated policy and actions pertaining to
development, health and communicable diseases at
global level. New trends in trade relations agreed to
under the Doha Development Agenda, new
commitments to increased Official Development
Assistance (ODA) agreed to at the 2002 International
Conference on Financing for Development in
Monterrey, innovative public and private research
initiatives and stronger partnerships in global
initiatives and with the UN have resulted from this.
Strengthening pharmaceutical policies
Optimal use of key pharmaceutical products in
confronting HIV/AIDS, malaria and tuberculosis is
essential to maximise the impact of interventions.
The European Commission is supporting WHO to
improve its essential drug policy and regulatory
schemes pertaining to the three diseases.
Untying of aid
‘Tied aid’ is given under certain conditions, for
example, that the recipient will use aid to purchase
goods and/or services from suppliers based in the
donor country. Untying aid means opening up those
purchases to suppliers based elsewhere. The
European Commission and the EU are in the process
of untying all ODA following the Communication on
untying of aid(
13) and the Conclusions of the
European Council(
14). This is already resulting in
greater efficiencies in some countries. 
Tiered pricing schemes have lowered
drug costs
The Commission’s proposal to examine how tiered
pricing can be used as a way to make on-patent
medicines more affordable within developing
countries, while taking into consideration the
concerns of the pharmaceutical companies was
welcomed at the Round Table in 2000.
Since then, global dialogue and visibility around the
issue of price for key pharmaceuticals still under
patent and competition of generic pharmaceuticals
have lowered prices of some of those products. At
the Round Table, price announcement was made by
a company of an annual cost of ￿500 per year for
anti-retrovirals. This was a major step forward from
the ￿10,000 annual cost previously estimated for
treatment including anti-retrovirals. For now, tiered
pricing is not used as widely as needed. Only 2% of
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5 Estimated price reductions offered to certain developing countries 
compared to retail price VAT excluded in Switzerland (November 2002)
Stavudine (BMS)
Lamivudina (GSK)
Ritonavir (Abbott)
Didanosine (BMS)
Efavirenz (MSD & BMS)
Indinavir (MSD)
Lamivusine & Zidovudine (GSK)
Zidovudine (GSK)
Nevirapine (BI)
Saquinavir (Roche)
Amprenavir (GSK)
Nelfinavir (Roche)
92
91
91
88
88
88
88
88
87
60
55
49
Source: European Commission. Global Fund data; July 2003patients in need from developing countries have
access to anti-retroviral treatments (1% in Africa).
This may change through the implementation of
May 2003 Regulation that seeks to prevent the re-
importing of reduced price pharmaceuticals into
Europe, which could allay industry’s fears. This
Regulation prohibits imports back to Europe of
pharmaceutical products that have been exported to
the poorest countries at prices reduced by at least
75% of the OECD average price or sold at production
cost plus maximum 15%.
Developing local manufacturing capacity
The European Commission is committed to support
initiatives promoting the local production of
condoms, long-lasting insecticide treated nets,
antiretrovirals, anti-malarial combination protocols
and anti-tuberculosis pharmaceuticals.
Taxes, tariffs and TRIPS
The European Commission is working closely with
developing countries to reduce or abolish taxes and
tariffs on imported key pharmaceutical products and
commodities.
The position of the European Commission and the
EU on the TRIPS agreement (Trade-Related Aspects
of Intellectual Property Rights) led to the adoption
of the Doha Declaration on the relationship between
TRIPs and public health. The Declaration, among
other things, gives Least Developed Countries the
right to postpone the implementation of patent
protection until 2016. In addition, the European
Commission negotiated within the TRIPS Council a
solution for those countries unable to make use of
compulsory licensing exceptions due to insufficient
or absent manufacturing capacities. 
In addition, the European Commission negotiated
within the TRIPS Council a solution for those
countries unable to make use of compulsory
licensing exceptions due to insufficient or absent
manufacturing capacities. The Doha Declaration on
the TRIPS Agreement and public health from 2001
gives developing countries certain freedom and
security in their choices of health policies. The Least
Developed Countries have also been authorised an
extension to provide for patents on pharma-
ceuticals until 2016. The decision passed in August
2003 supplements the Doha Declaration by giving
World Trade Organisation member countries the
freedom to export pharmaceuticals under a
compulsory license to countries which are not in a
position to produce the products under such a
license loyally.
Public and Private Research priorities
To achieve the international targets for each disease
and the related Millennium Development Goals, the
world needs diagnostics, microbicides, vaccines and
pharmaceuticals that are more effective for malaria,
of shorter duration for people with tuberculosis, and
more user friendly for those suffering from
HIV/AIDS. This can be achieved through better-
targeted research in public institutions and private
industry.
18The 6t
h Research Framework Programme
and EDCTP
In July 2002, the European Commission adopted the
6th Framework Programme for Research (SFP2002-
2006). Some ￿400 million will target HIV/AIDS,
malaria and tuberculosis research projects (2.5% out
of a total  ￿17.5 billion). Of the ￿400 million allocated
under the 6
thResearch Framework, ￿200 million will
be allocated to the European and Developing
Countries Clinical Trials Partnership (EDCTP). The
EDCTPincludes strong elements of capacity building
in developing countries, particularly in the areas of
networking and co-operation, technology transfer,
strengthening clinical research capacities, and
initiating and developing clinical testing facilities.
Direct or indirect incentives for private sector
increased investments in the development of
products to counter the three diseases are also
further pursued. 
In particular, incentives need to be strengthened for
private sector investments in new ‘economically
orphan’medicines for communicable diseases with
highest burden in developing countries.
Despite widespread recognition of the problem,
a multitude of ideas, and some years’discussion of
the need to promote and create stronger R&D
incentives for ‘economically orphan’ medicines for
communicable diseases, there is little if any
evidence that existing or proposed incentives have
had a significant impact. Existing treatments remain
woefully inadequate and communicable diseases
remain responsible for one in two deaths in
developing countries, often among the young and
most productive population – 90% of these deaths
are due to the six most prevalent communicable
diseases: tuberculosis, malaria, diarrhoeal diseases,
pneumonia, measles, and HIV/AIDS. 
19Revisiting the strategy for EU aid in 1999, the
European Community concluded that the scope and
the size had to be increased. At the same time, it
was decided that the EU should also work in closer
partnership with key stakeholders and institutions.
If the three epidemics are to be successfully
tackled, we must share responsibility and work
together.
As a result, activities have been undertaken to
foster stronger partnerships with EU Member
States; civil society; the private sector; the UN; the
World Bank, and the European Investment Bank. 
The European Community and its Member States
have been proactive in confronting the three
diseases at international level such as at G8(
15)
Summits, the follow-up to the Cairo Plan of Action
within the European Union/African Union forum, the
Least Developed Countries’Conference in Brussels
in 2001, the UNGASS on HIV/AIDS in 2001, the
Barcelona AIDS Conference in 2002, the Doha WTO
Ministerial, the Monterrey Conference and the
Johannesburg World Summit on Sustainable
Development.
Dialogue with civil society is stronger at policy and
programme level. Pharmaceutical companies are
increasingly involved as partners in policy and
implementation, in particular in areas such as
corporate social responsibility, tiered pricing and
research and development. Other private sector
partners, such as Investors for Africa, are working
with the European Commission/European Union on
confronting communicable diseases in developing
countries.
A number of EU policy documents and Commu-
nications adopted by the European Parliament(
16)
call for a greater and improved co-ordination and
effectiveness in the delivery of development
assistance. The EU Council in Barcelona agreed to
take concrete steps in this area by 2004. 
The EU and the Global Fund to Fight
HIV/AIDS, Tuberculosis and Malaria
UN Secretary General Kofi Annan and the global
community called for increased financial resources
to scale up and confront the three diseases through
a Global Fund to Fight HIV/AIDS, Malaria and
Tuberculosis (GFATM(
17)). The Global Fund was
created at the G8 in 2001, with the European
Commission and most Member States taking an
active part in shaping and financing the new global
partnership. The Global Fund pays special attention
to the demand of the developing countries, the
participation by civil society, people living with the
diseases and private partnerships. It encourages the
supply of low-cost, high-quality products to
countries of the South, including distribution of
generic products. It aims at ensuring openness,
transparency and innovation in administration, in co-
operation with all the main players.
(15)
The European Commission /
G8 EU Member States
consensus was clearly
demonstrated during the
negotiations leading to the
G8 Summits in Okinawa
(2000), Genoa (2001),
Kananaskis (2002) 
and now preparing for Evian
(2003), with the Okinawa
Communiqu  presenting
the most comprehensive
global approach to tackling
the three diseases.
(16)
1999: ‘Complementarity
between Community and
Member States policies on
development co operation’,
2000: ‘European Commu 
nity development policy’
and 2002: ’Health and
poverty reduction in develo 
ping countries’.
(17)
www.gfatm.org
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The EU Co-ordination 
and Global PartnershipsGlobal public goods in health
In an increasingly globalised world, populations are
more at risk, more dependent on each other and
more aware of the shared risk. Recently, global public
goods in health have been the subject of increased
international attention because of HIV/AIDS and
other global risks caused by diseases prevalent
mainly in developing countries. 
The European Commission’s Programme for Action
identifies a number of ways in which the EU intends
to develop better rules, incentives and financial
instruments for the development of specific global
public goods. For example:
• Incentive package for the development of new
products to confront the major communicable
diseases in developing countries.
• Economic research into the demand for specific
global public goods for developing countries.
• Co-operation with other partners on developing
an AIDS vaccine.
In the European Commission’s Communication on
Health and Poverty Reduction in Developing
Countries (
18) ‘investing in the development of specific
global public goods’ is identified as one of four
objectives of health and poverty policy. Further work
is ongoing.
Working in partnership with IAVI 
and the IPM
The International AIDS Vaccine Initiative (IAVI) and
the International Partnership for Microbicides (IPM)
are global organisations working to speed the
development and distribution of preventive AIDS
vaccines and microbicides. They focus on mobilising
support through advocacy and education, accele-
rating scientific progress, encouraging industrial
participation in AIDS vaccine and microbicides
development, and assuring access in developing
countries.
IAVI and IPM are key partners in the European
Commission’s Programme for Action, and the
European Commission is member of the policy
advisory board for both organisations. 
The European Commission is supporting the South
African Aids Vaccine Initiative (SAAVI), through a
programme where IAVI is a partner with ￿1.35 million
to intensify the vaccine preparedness programme in
South Africa, building on the previously European
Commission -funded SA HIVAC project. 
The European Commission has also programmed
support with ￿3 million to IAVI for vaccine
preparedness programmes (ethical criteria,
regulatory aspects, preparedness of communities)
for the introduction of phase III trials of an effective
and safe HIV/AIDS vaccine (DNA MVA) in East Africa.
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Communication of the
Commission to the Council
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Countries Brussels,
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COM(2002) 129.Corporate Social Responsibilities (CSR)
A European Multi-stakeholder Forum was recently
launched by the Commission to promote CSR
through fostering a dialogue among the business
community, trade unions, civil society organisations
and other stakeholders (44 member organisations
plus 10 observers). It has the specific aim of raising
awareness on and possibly promoting CSR practices
and instruments, taking into account existing EU
initiatives and internationally agreed instruments. 
The Forum’s work is organised through four area-
based Round Tables, including one on development
aspects of CSR. Confronting the three diseases is a
key concern of this forum.
22Towards increased ODA aiming 
at social development
Donor countries committed to increasing official
development assistance (ODA) to developing
countries in March 2002 at the International
Conference on Financing for Development held in
Monterrey, Mexico. According to OECD estimates,
fulfilling these promises would raise ODA in real
terms by 31% (about ￿13.42 billion) and the
ODA/GNI (gross national income) ratio to 0.26%.
The EU Barcelona commitment is 0.39% by 2006. 
Member countries of the OECD's Development
Assistance Committee increased their official
development assistance to developing countries by
4.8% in real terms (EU: 2.8%), accounting for
inflation, from 2001 to 2002. The total amounted to
￿47.8 billion (more than 60% from the EU),
equivalent to 0.23% (EU: 0.34%) of their combined
resources, measured as gross national income
(GNI) and some ¤10 per capita. This marks the
beginning of a recovery from the all-time lows of
0.22% of GNI in each of the last three years. The
spending on health, education and populations
accounts for 15% of the global ODA. 
Leading up to the International Conference on
Financing for Development in Monterrey, the EU
made a commitment at the European Council in
Barcelona 2002 to increase allocations for ODA,
especially for aid supporting social development, as
well as improved co-ordination of polices and
programmes. 
European Commission country 
programming in health
The new generation of EC Country Strategy Papers
programme ODA in partnership with developing
countries for a total almost￿13 billion through 2004
to 2007, depending on the region. Seventeen
developing countries have identified health as a
focal sector in Country Strategy Papers for 2002-
2007 that, as of July 2003, have been approved.
Overall allocations for health in national indicative
programmes are 3.3% of total programmable
resources or ￿431 million. In ACP countries
allocations specifically for health account for 4.1%
of programmable resources (￿288,1 million). 
However, European Community funds are
increasingly devoted to general budget support –
especially in the ACPcountries where 24.4% of total
programmable resources (￿1.73 billion) are
allocated to it. The Commission’s guidelines on
health sector programming and monitoring of
indicators aim at ensuring the links between
poverty reduction budget support strategies and
improved health outcomes.
Regional contribution from intra ACP funds have
increased since the adoption of the programme for
action, especially regarding the ACP countries: for
the period 2003-2007, almost ￿300 million is
envisaged to support inter-regional health initiatives,
a large proportion of it related to HIV/AIDS, malaria
and tuberculosis.
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Increased financial resources mobilised The European Commission increases
resources to control HIV/AIDS, 
tuberculosis and malaria
In addition to the European Commission’s support
to health and specific programmes on HIV/AIDS,
malaria and tuberculosis through country and
regional strategies, the European Community has
other financial tools that support specific actions:
• The budget line to support innovative initiatives
to control HIV/AIDS, malaria and tuberculosis.
• The European Commission’s co-financing budget
line for NGOs selects some projects in regions or
situations where other EC instruments are not
feasible.
• Various European Commission humanitarian aid
programmes specifically target actions on
poverty-related diseases.
• The European Commission’s support for research
activities specifically allocates resources to the
fight against these diseases, focusing on their
development approach and in partnership with
developing countries.
Overall, the total estimated allocation to European
Commission programmes specifically targeting
HIV/AIDS, malaria and tuberculosis over the last nine
years (1994-2002) has been ￿660 million(
19). This
annual average of ￿73 million per year represents
13% of the European Commission’s annual support
to health in developing countries (annual average of
￿625 million for the same period).
The breakdown during the period is: 40% from
geographical budget lines, 32% from research, 15%
from NGO co-financing and 13% from the special
budget line on HIV/AIDS and population. The
distribution of this specific support to poverty-
related diseases by type of disease is: 71% for
HIV/AIDS, 17% for malaria and 12% for tuberculosis.
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5 Total pledges to the Global Fund 
(US dollars, 23 july 2003)
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Source : European Commission. 
Global Fund data, July 2003
5 EC/EU pledge to the global Fund
(US dollars, 23 july 2003)
Austria
Belgium
Denmark
European Commission
France
Germany
Grece
Ireland
Italy
Luxembourg
Netherlands
Spain
Sweden
United Kingdom
Source: European Commission. 
Global Fund data, July 2003
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This figure is an under 
estimate as there is a
proportion of the Repro 
ductive Health
Programmes that targets
HIV/AIDS, such as that
preventing MTCT or
controlling STDs, neither
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2.576.751.814
1.625.000.000
200.000.000
208.410.600
1.589.286
1.617.940
525.635.814
628.571.429 428.571.429
3.275.177
153.317.657
50.000.000
71.452.313
304.881.945
1.075.900
19.064.552 27.893.434
341.629.504
285.714
21.096.946
100.147.568Total pledges to the Global Fund by July 2003
reached ￿3.93 billion , of which ￿2.20 billion (55%
of total pledges) comes from the 15 EU Member
States together with the European Commission   and
￿1.38 billion from the United States. The European
Commission has disbursed ￿120 million for 2002 and
has announced an additional sum of ￿340 million for
years 2003-2006.
The total European Commission’s pledge of ￿460
million corresponds to more than one tenth of the
current total pledges (as of July 2003), and
reconfirms the European Commission as an
important contributor.
Altogether, the various development, humanitarian
and research European Commission’s financial
instruments to confront HIV/AIDS, malaria and
tuberculosis, will total ￿1117 million (an annual
average of ￿280 million) during the period 2003-
2006, representing an almost four fold increase.
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European Commission support to innovative initiatives 
A ￿22 million programme aimed at young people
In August 2002, the European Commission announced a further contribution of ￿22 million for the fight
against HIV/AIDS in developing countries in a call for proposal under the AIDS Budget Line 2002. This
programme aims primarily at young people in the areas of prevention, care and treatment. Special attention
is given to the needs of young women who are especially vulnerable to HIV/AIDS infection.
The objective of this initiative is to ensure that operations aimed at confronting HIV/AIDS are made more
effective, particularly by improving education and information and strengthening health systems. It comes
as an additional contribution to the implementation of the Programme for Action adopted early in 2001 to
fight against HIV/AIDS, malaria and tuberculosis.
European Commission support involves the following activities:
• Information, education and communication contributing to a change of behaviour while taking into
account the constraints of the socio-economic and cultural context.
•I mprovement of access to and quality of health services benefiting the young, particularly young women,
and decreasing the vulnerability to infection by HIV through a combination of action, research and training
aimed at organising and developing health services.
• Integration of the gender equality strategy at the level of health systems and in favour of programmes
to fight HIV/AIDS benefiting the young. Tackling the questions related to sexual relations, particularly
where young women are at risk due to biological*, social and economic factors, including diverse forms
of violence at home, at school and in the workplace. 
The implementation of this additional program is being carried out through private, public, national or/and
international non-profit organisations such as DANCHURHAID, World Vision Netherlands, OXFAM UK,
Population Concern, Care Austria, and Institute of Tropical Medicine of Antwerp.
* Women are at higher risk than men for HIV transmission through unsafe heterosexual contacts.Emergency humanitarian programmes respond to health needs
Responding to post-epidemic needs in Burundi
After assisting several partners in their emergency response to the malaria epidemic in Burundi during 2001,
ECHO continues to support the post-epidemic response. In July 2002, Burundi amended its malaria national
treatment protocol due to very high resistances to the medications used up until that point (pirimethamine-
sulphadoxine and chloroquine). 
New medications (arthemether and amodiaquine) are to be introduced after a period of health staff training
and public awareness campaigns. The introduction presents a formidable challenge, not only because
appropriate use of the drugs is essential to avoid the development of new resistances, but also because
of the financial side of the operation, which carries a price tag of from ￿0.20 to ￿1.60 per treatment.
ECHO financed interventions range from preventive to curative efforts. Preventive efforts are financed mainly
through UNICEF and include such measures as distribution of insecticide-treated nets and awareness
campaigns focusing on water and sanitation in conjunction with several NGOs. Curative efforts involve the
financing of anti-malarial drug stocks for routine treatment in health centres and as emergency stocks in
the event of epidemics (contingency stocks of CO-artem, the most effective anti-malarial). 
The fight against malaria will remain a priority for ECHO interventions in the country. ECHO will support
the introduction of the new malaria protocol through several UNICEF and NGO partners. It will also finance
new medications for use in health centres and as stock in the event of epidemics, as well as diagnostic
tools such as the rapid test called ‘par-check’).
27Co-financing budget line supports NGOs 
Supporting NGOs in Nepal
In early January 2001, International Nepal Fellowship, a Christian relief and development charity registered
in Birmingham (UK) since 1963, started the Tuberculosis Leprosy Project in Birendranagar, Surkhet Nepal,
together with Tear Fund Ltd., another UK development NGO. The duration of the project is 60 months and
the total cost slightly more than ￿5 million, to which the European Commission is contributing ￿1.9 million.
The project is providing cost-effective health education, early detection and treatment. Target beneficiaries
include women of reproductive age, men in the working sector and children within the context of healthy
families. (Direct beneficiaries: 300,000 outpatients and 20,000 treated patients, 500 trained volunteers,
and 28 scholarship-funded staff members. Indirect beneficiaries: 14,000 families with two surviving parents
around 70,000 people, TB/Leprosy awareness seminars presented to 15,000 women and AIDS/HIV seminars
for 2,000 students). 
This project incorporates the national tuberculosis programme established by WHO, the national
comprehensive leprosy training and control programme of HMG Nepal, and will operate in close conjunction
with the Regional Health Directorate. DOTS strategy and the EPI Centre reporting system are the working
tool references for TB, and LEC and SAPEL will be followed, both promoted by WHO as appropriate
programmes for fighting leprosy.
Various national and international NGOs involved in leprosy work in Nepal have formed the network of
Leprosy NGOs. In addition, the TB network has recently facilitated a successful international conference
(TB Net).
28Supporting research projects in developing countries
Preventive and therapeutic products ready for trial
The European Commission’s 5
thResearch Framework Programme has pushed new preventive and therapeutic
products that are ready to benefit from the European and Developing Countries Clinical Trials Partnership
(EDCTP) and other sources.
The most relevant advances on HIV/AIDS research supported by the 5
thResearch Framework is the progress
of HIV/AIDS vaccine candidates to human trials. Three promising candidates of the type DNA-virus carrier
(MVA and NYVAC) are now ripe for Phase I in China (seroptype C), Europe (serotype B) and Tanzania (serotype C),
and will most likely be ready for Phase II early in 2004. They will be well positioned for further Phase III
trials within the upcoming EDCTP in the coming years, signalling potential progress within this decade
towards an effective HIV/AIDS vaccine. This is being carried out in close co-ordination with other global
initiatives, particularly IAVI (the International AIDS Vaccine Initiative).
Progress has also been made on three candidate TB vaccines based on fusion proteins and protein subunits.
These vaccines will also enter human trials and hopefully result in an effective TB vaccine. 
As regards malaria, the main achievement has been the pre-clinical trials of new families of potentially
effective anti-malarials, such as the phospholipid synthesis inhibitors, which will also enter human trials. 
29While the effects of HIV/AIDS, malaria and
tuberculosis are felt most acutely by affected
individuals families and communities, the extent and
severity of these diseases means that they
undermine development efforts in many countries
and indeed are global threats to public health and
security. 
To confront these three and other emerging diseases
effectively we need an effective, co-ordinated
response at all levels. The new millennium has
brought a renewed international commitment to this
response, and the international community has
agreed ambitious targets to be achieved by 2015. 
The European Community wholeheartedly supports
the Millennium Development Goals and has placed
the fight against poverty at the centre of its
development policy. The European Commission’s
development principles place a high premium on
national ownership of development programmes and
partnership with all key stakeholders, including the
major donors. In this vein, the European Commission
has striven to use its comparative advantage in
specific areas – such as development, trade policy
and research – to help create more favourable
conditions for developing countries to be able
respond effectively to three diseases. The set of
actions described in this brochure comprises the core
of the European Commission’s response as set out
in the EU Action Programme in February 2002. 
The new approach is only just beginning to bear fruit.
The European Commission’s policy on tiered pricing
of key medicines has already facilitated dramatic
price reductions in key anti-retroviral and anti-
malarial drugs for developing countries. The
European Union has strongly supported the right of
countries to override intellectual property rights
when public health is under threat. However, it will
be several years at least before European
Commission support for essential research into
global public goods such as an AIDS vaccine or new
anti-malarial drugs will lead to the manufacture of
usable products that are available and accessible for
those with the highest need.
We continue to face many challenges. First, we must
recognise that the three diseases will only be
effectively confronted where there are effective
public systems in place to do so. Households,
communities and even countries will not be able to
take effective action on alone. Only concerted
national and international efforts will make the
achievement of the Millennium goal of confronting
HIV/AIDS, malaria and tuberculosis a reality.
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The way forwardA related challenge is to provide adequate resources
to enable countries to scale up programmes to
confront the three diseases, and to take full
advantage of reduced priced medicines and other
commodities. Health expenditure in the world’s
poorest countries remains far below what is needed
to sustain effective basic health services. At
Monterrey in March 2002, the worlds’ leaders
agreed to revitalise efforts to mobilise resources,
recognising that a ‘substantial increase’in overseas
development assistance (ODA) was required,
especially to the world’s poorest countries. They
reaffirmed the United Nations’ target of developed
countries committing at least 0.7% of their GNP as
ODA. The leaders of the European Union Member
States at the Barcelona summit subsequently
endorsed this commitment. 
In Barcelona EU leaders also made a commitment to
intensify efforts to harmonise policies and
operational procedures, to untie aid, to work with
nationally driven and owned development frame-
works, and to improve targeting of the poor. Much
work remains to be done to carry forward these
commitments for the benefit of developing nations.
The need for concerted and co-ordinated inter-
national action to confront communicable diseases
was recognised over a hundred years ago, when the
first international sanitary conferences were
organised in the face of the cholera pandemics. The
HIV/AIDS pandemic, the growing threat posed by
tuberculosis, the worsening malaria situation – as
well as the other diseases such as polio and the
possibility of emerging threats such as SARS – all
once again reinforce the case for robust international
public action and, indeed, action all levels. 
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We cannot afford complacency . . . 
. . .  even for a moment.European Commission regional and country strategy papers (CSPs): 
http://europa.eu.int/comm/development/body/csp_rsp/csp_en.cfm
Information on calls for proposals under the budget-lines:
http://europa.eu.int/comm/europeaid/index_en.htm
Millennium Development Goals:
http://www.un.org/millenniumgoals/
Programme for Action (PfA), ‘Accelerated action on HIV/AIDS, malaria and TB 
in the context of poverty reduction’, February 2001:
http://europa.eu.int/eur-lex/en/com/cnc/2001/com2001_0096en01.pdf
Progress Report on the PfA, February 2003:  
http://europa.eu.int/eur-lex/en/com/cnc/2003/com2003_0093en01.pdf 
Reports from the Commission on Macroeconomics and health: 
http://www.who.int/macrohealth/en/
WTO and TRIPS: 
http://www.wto.int/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm
Regulation ‘to avoid trade diversion into the EU market of certain key medicines’:
http://europa.eu.int/eur-lex/pri/en/oj/dat/2003/l_135/l_13520030603en00050011.pdf
European and Developing Countries Clinical Trial Partnership (EDCTP) programme (DG Research):
http://europa.eu.int/comm/research/info/conferences/edctp/edctp_fp6_en.html
The Global Fund to fight AIDS, TB and Malaria (GFATM): 
http://www.globalfundatm.org
Human and Social Development Unit (DG Development):
http://europa.eu.int/comm/development/development_old/sector/social/health_en.htm
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Useful web-linksAIDS
Acquired Immune Deficiency Syndrome
ARV
Anti-Retroviral 
CSPs
Country Strategy Papers
CSR
Corporate Social Responsibility
DOTS
Directly Observed Treatment, Short-course
ECHO
European Community Humanitarian Aid Office
EDCTP
European and Developing Countries Clinical
Trials Partnership
G8
Group of G7 most industrialised countries 
and Russia
GFATM
Global Fund Against AIDS, Tuberculosis and
Malaria
HAP
Health, AIDS and Population
HIV
Human Immune Deficiency Virus
HIVAC
HIV vaccine
IAVI
International AIDS Vaccine Initiative
IPM
International Partnership for Microbicides
ITNs
Insecticide Treated Nets
MDGs
Millennium Development Goals
MDR
Multi-drug resistant
ODA
Official Development Assistance
OECD
Organisation for Economic Co-operation 
and Development
R&D
Research and Development
RTD
Programme for Research and Technological
Development and Demonstration 
SAAVI
South African Aids Vaccine Initiative
SARS
Severe Acute Respiratory Syndrome
TB
Tuberculosis
TRIPS
Trade-Related Aspects of Intellectual 
Property Rights
UNAIDS
United Nations Joint Programme on HIV/AIDS
UNCTAD
United Nations Conference on Trade 
and Development
WHO
World Health Organisation
WTO
World Trade Organisation
AbbreviationsEuropean Commission
Directorate-General for Development
Postal address: rue de la Loi, 200 – B-1049 Brussels (Belgium)
Office address: rue de Genève 12 – B-1140 Brussels (Belgium)
Fax: +32.2.299.25.25
E-mail: development@cec.eu.int
Internet: http://europa.eu.int/comm/development/index_en.htm
9￿7￿ 8￿ 9￿ 2￿ 8￿ 9￿4￿ 5￿ 3￿ 2￿ 3￿ 3￿>
European Commission
Luxembourg: Office for Official Publications of the European Communities
2003 — 32pp. — 29,7X21 cm
ISBN : 92-894-5323-0
N
H
-
5
1
-
0
3
-
7
7
0
-
E
N
-
C